{"pageContent": "Background: Metastatic prostate cancer (PCa) is associated with considerable diminished overall survival (OS). Standard treatment for metastatic PCa has long been androgen deprivation therapy alone, with patients initially responding to this treatment and then progressing to a castration-resistant phase.", "metaData": {"source": "[Localized prostate cancer]\nhttps://pubmed.ncbi.nlm.nih.gov/12731435/"}}